全文获取类型
收费全文 | 9336篇 |
免费 | 560篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 107篇 |
儿科学 | 271篇 |
妇产科学 | 245篇 |
基础医学 | 1428篇 |
口腔科学 | 307篇 |
临床医学 | 1016篇 |
内科学 | 1822篇 |
皮肤病学 | 219篇 |
神经病学 | 970篇 |
特种医学 | 348篇 |
外科学 | 1040篇 |
综合类 | 39篇 |
一般理论 | 2篇 |
预防医学 | 709篇 |
眼科学 | 136篇 |
药学 | 580篇 |
中国医学 | 18篇 |
肿瘤学 | 680篇 |
出版年
2024年 | 10篇 |
2023年 | 79篇 |
2022年 | 137篇 |
2021年 | 258篇 |
2020年 | 199篇 |
2019年 | 231篇 |
2018年 | 237篇 |
2017年 | 196篇 |
2016年 | 257篇 |
2015年 | 276篇 |
2014年 | 370篇 |
2013年 | 482篇 |
2012年 | 773篇 |
2011年 | 820篇 |
2010年 | 435篇 |
2009年 | 400篇 |
2008年 | 628篇 |
2007年 | 664篇 |
2006年 | 569篇 |
2005年 | 608篇 |
2004年 | 559篇 |
2003年 | 489篇 |
2002年 | 440篇 |
2001年 | 77篇 |
2000年 | 55篇 |
1999年 | 71篇 |
1998年 | 97篇 |
1997年 | 69篇 |
1996年 | 36篇 |
1995年 | 51篇 |
1994年 | 46篇 |
1993年 | 34篇 |
1992年 | 30篇 |
1991年 | 19篇 |
1990年 | 20篇 |
1989年 | 16篇 |
1988年 | 14篇 |
1987年 | 12篇 |
1986年 | 13篇 |
1985年 | 13篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 23篇 |
1981年 | 16篇 |
1978年 | 13篇 |
1977年 | 8篇 |
1976年 | 9篇 |
1974年 | 7篇 |
1969年 | 7篇 |
1968年 | 6篇 |
排序方式: 共有9937条查询结果,搜索用时 15 毫秒
41.
The aim of the present study was to investigate whether amperozide, an antipsychotic drug which possesses anti-aggressive and anxiolytic-like properties, stimulates the secretion of oxytocin and if so, by which receptor mechanism. For this purpose, female or male Sprague Dawley rats were given amperozide (0.5, 2.5 and 5.0 mg/kg IP), ritanserin (5.0 mg/kg), raclopride (2.0 mg/kg) and prazosin (1.0 mg/kg) and were subsequently decapitated for collection of blood (30 and 120 min) after injection. Oxytocin levels were measured with radioimmunoassay. Amperozide 2.5 and 5 mg/kg increased plasma levels of oxytocin significantly (P<0.05 and <0.001). The effect appeared maximal about 30 min after injection of the drug and oxytocin levels were almost back to basal within 120 min. Similar effects were obtained in female and male rats as well as in animals that were freely fed or food deprived for 24 h. CSF levels of oxytocin were also increased. Ritanserin, a 5-HT2-receptor antagonist but not the D2 receptor antagonist raclopride or the 1-adrenoceptor antagonist prazosin stimulated oxytocin release. In addition, clozapine, a neuroleptic with potent HT2-antagonistic properties, was a potent releaser of oxytocin, whereas haloperidol was without effect. A possible role for oxytocin in the behavioural effects of amperozide and clozapine remains to be explored. 相似文献
42.
Athanassios Argiris Bruce E Brockstein Daniel J Haraf Kerstin M Stenson Bharat B Mittal Merrill S Kies Fred R Rosen Borko Jovanovic Everett E Vokes 《Clinical cancer research》2004,10(6):1956-1962
PURPOSE: The purpose of this retrospective analysis was to evaluate the emergence of second primary malignancies and the contribution of different causes of death to the outcome of patients with locoregionally advanced head and cancer receiving primary chemoradiotherapy. EXPERIMENTAL DESIGN: We studied 324 patients with stage IV squamous cell head and neck cancer who were enrolled on five consecutive multicenter Phase II studies of concurrent chemoradiotherapy. All of the regimens included concurrent 5-fluorouracil and hydroxyurea on an alternate week schedule with radiotherapy, either alone (FHX) or with cisplatin (C-FHX) or paclitaxel (T-FHX). The cumulative incidence of second primary tumors or death from any cause was estimated using methods of competing risk analysis. RESULTS: Median follow-up of surviving patients was 5.2 years (2-10.6 years). The 5-year overall survival and progression-free survival of the cohort were 46% and 65%, respectively. Causes of death and median time of occurrence were as follows: disease (n = 88; 1.5 years), treatment-associated acute or late complications (n = 30; 4 months), second primary tumors (n = 18; 3.5 years), comorbidities (n = 41; 1.9 years), and unknown (n = 20; 5.1 years). Predominant causes of death from comorbidities were cardiac and respiratory illnesses. Twenty-six patients (8%) developed a second primary tumor at a median time of 2.8 years (4 months to 10 years). The cumulative incidence of second primary tumors was 5%, 7%, and 13% at 3, 5, and 10 years, respectively. The most frequent site of second primaries was the lung (n = 13), followed by the esophagus (n = 3) and head and neck (n = 2) CONCLUSIONS: Patients with locoregionally advanced head and neck cancer treated with concurrent chemoradiotherapy are potentially curable but face significant risks of mortality from causes other than disease progression. Ameliorating toxicity, and implementing secondary screening and chemoprevention strategies are major goals in the management of head and neck cancer. 相似文献
43.
Everett E Vokes Kerstin Stenson Fred R Rosen Merrill S Kies Alfred W Rademaker Mary Ellyn Witt Bruce E Brockstein Marcy A List Bing Bing Fung Louis Portugal Bharat B Mittal Harold Pelzer Ralph R Weichselbaum Daniel J Haraf 《Journal of clinical oncology》2003,21(2):320-326
PURPOSE: The paclitaxel, fluorouracil, and hydroxyurea regimen of paclitaxel, infusional fluorouracil, hydroxyurea, and twice-daily radiation therapy (TFHX) administered every other week has resulted in 3-year survival rates of 60% of stage IV patients. Locoregional and distant failure rates were 13% and 23%, respectively. To reduce distant failure rates, we added a brief course of induction chemotherapy to TFHX. PATIENTS AND METHODS: Sixty-nine patients received six weekly doses of carboplatin (AUC2) and paclitaxel (135 mg/m2) followed by five cycles of TFHX. RESULTS: Ninety-six percent had stage IV disease. Response to induction chemotherapy was partial response 52% and complete response (CR) 35%. Symptomatically, there was a significant reduction in mouth and throat pain. The most common grade 3 or 4 toxicity was neutropenia (36%). Best response following completion of TFHX was CR in 83%. Toxicities of TFHX consisted of grade 3 or 4 mucositis (74% and 2%) and dermatitis (47% and 14%). At a median follow-up of 28 months, locoregional or systemic disease progression were each noted in five patients. The overall 3-year progression-free survival was 80% (95% confidence interval [CI], 71% to 90%), and the 2- and 3-year overall survival rates were 77% (95% CI, 66% to 87%) and 70% (95% CI, 59% to 82%), respectively. At 12 months, five patients were completely feeding-tube dependent. CONCLUSION: Administration of carboplatin and paclitaxel before TFHX chemoradiotherapy results in high response activity and may decrease distant failure rates. Overall survival, progression, and organ preservation/functional outcome data support definitive evaluation of this approach. 相似文献
44.
45.
Janne L?hdesm?ki Jukka Sallinen Ewen MacDonald Mika Scheinin 《Neuropsychopharmacology》2004,29(7):1282-1293
Amphetamines are commonly used to treat attention-deficit hyperactivity disorder, but are also widely abused. They are employed in schizophrenia-related animal models as they disrupt the prepulse inhibition (PPI) of the acoustic startle response. The behavioral effects of amphetamines have mainly been attributed to changes in dopamine transmission, but they also involve increases in the synaptic concentrations of norepinephrine (NE). alpha2-Adrenoceptors (alpha2-ARs) regulate the excitability and transmitter release of brain monoaminergic neurons mainly as inhibitory presynaptic auto- and heteroreceptors. Modulation of acoustic startle and its PPI by the alpha2A-AR subtype was investigated with mice lacking the alpha2A-AR (alpha2A-KO) and their wild-type (WT) controls, without drugs and after administration of the alpha2-AR agonist dexmedetomidine or the antagonist atipamezole. The interaction of D-amphetamine (D-amph) and the alpha2-AR-noradrenergic neuronal system in modulating startle reactivity and in regulating brain monoamine metabolism was assessed as the behavioral and neurochemical responses to D-amph alone, or to the combination of D-amph and dexmedetomidine or atipamezole. alpha2A-KO mice were supersensitive to both neurochemical and behavioral effects of D-amph. Brain NE stores of alpha2A-KO mice were depleted by D-amph, revealing the alpha2A-AR as essential in modulating the actions of D-amph. Also, increased startle responses and more pronounced disruption of PPI were noted in D-amph-treated alpha2A-KO mice. alpha2A-AR also appeared to be responsible for the startle-modulating effects of alpha2-AR drugs, since the startle attenuation after the alpha2-AR agonist dexmedetomidine was absent in alpha2A-KO mice, and the alpha2-AR antagonist atipamezole had opposite effects on the startle reflex in alpha2A-KO and WT mice. 相似文献
46.
Athanasia Apsemidou Kerstin Rauwolf Athanasios Tragiannidis Angela Brentrup Manfred Schiborr Karsten Becker Martina Ahlmann Andreas H. Groll 《Pediatric blood & cancer》2019,66(4)
Bartonella henselae, the causative agent of cat‐scratch disease, has been recognized to be responsible for a broad range of clinical syndromes. We report the case of a patient with disseminated B. henselae infection mimicking Langerhans cell histiocytosis at presentation and its successful management with neurosurgery, prolonged antibacterial therapy, and observation. 相似文献
47.
Rita K. Schmutzler Bjrn Schmitz-Luhn Bettina Borisch Peter Devilee Diana Eccles Per Hall Judith Balmaa Stefania Boccia Peter Dabrock Günter Emons Wolfgang Gaissmaier Jacek Gronwald Stefanie Houwaart Stefan Huster Karin Kast Alexander Katalinic Sabine C. Linn Sowmiya Moorthie Paul Pharoah Kerstin Rhiem Tade Spranger Dominique Stoppa-Lyonnet Johannes Jozef Marten van Delden Marc van den Bulcke Christiane Woopen 《Breast care (Basel, Switzerland)》2022,17(2):208
BackgroundRisk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action.SummaryTherefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept. 相似文献
48.
Shinichiro Asakawa Shigeyuki Arai Mika Kawagoe Chiaki Ohata Wataru Ono Hiroshi Murata Yoshifuru Tamura Shunya Uchida Shigeru Shibata Yoshihide Fujigaki 《Internal medicine (Tokyo, Japan)》2022,61(9):1423
A young woman with microscopic polyangiitis (MPA) requiring hemodialysis showed repeated posterior reversible encephalopathy syndrome (PRES) with spatiotemporal multiple lesions over a period of two months. The first PRES episode with confusion and the second PRES episode with vertigo and nausea were caused by MPA, hypertension and renal failure. These symptoms were improved by the reinforcement of MPA treatment and blood pressure management. The third PRES episode with nausea, headache, seizure and visual changes was induced by rituximab infusion and hypertension. The PRES was improved with blood pressure and convulsant management. These conditions are challenging to diagnose and treat. 相似文献
49.
Justyna D. Kowalska Carlo Biekowski Luk Fleischhans Sergii Antoniak Agata Skrzat-Klapaczyska Magdalena Suchacz Nikolina Bogdanic Deniz Gokengin Cristiana Oprea Igor Karpov Kerstin Kase Raimonda Matulionyte Antonios Papadopoulos Nino Rukhadze Arjan Harxhi David Jilich Botond Lakatos Dalibor Sedlacek Gordana Dragovic Marta Vasylyev Antonia Verhaz Nina Yancheva Josip Begovac Andrzej Horban 《Viruses》2022,14(5)
50.
Marcus Knorr Michael Völker Peter Oliver Denk Kerstin Wunderlich Hans-Jürgen Thiel 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》1997,235(10):667-671
Background: Although platelet-derived growth factor (PDGF) has been thought to be critical in the wound-healing response of Tenon's capsule fibroblasts after glaucoma filtration surgery, no information is currently available concerning the proliferative effect of PDGF isoforms on this cell type. The aim of the present study was to evaluate the proliferative effect of PDGF-AB heterodimer and PDGF-AA and -BB homodimers on cultured human Tenon's capsule fibroblasts. Methods: Human Tenon's capsule fibroblasts, cultured under serum-free conditions, were stimulated with PDGF-AA, -AB and -BB isoforms in concentrations ranging from 1 to 100 ng/ml. Cell numbers were determined on days 1, 3, 5 and 7, using a cell counter. Results: Addition of PDGF-AB and -BB led to a dosedependent increase in cell proliferation. A maximal response (79.9% over control) was obtained after 7 days with 30 ng/ml of PDGF-BB, with an EC50 of 8.9 ng/ml. The maximal increase in cell proliferation caused by PDGF-AB (30 ng/ml) was 54.9%, with an EC50 of 12.5 ng/ml. Stimulation with PDGF-AA revealed a significant effect only with concentrations higher than 30 ng/ml. Conclusion: Our results indicate that PDGF-AB and -BB isoforms are potent stimulators of proliferation of human Tenon's capsule fibroblasts, suggesting that PDGF-AB and -BB isoforms play an important role in the wound-healing response after glaucoma filtration surgery.Presented in part at the annual meeting of the Deutsche Ophthalmologische Gesellschaft, Mannheim, September 1996 相似文献